CClinicalTrials.gg
RecruitingNCT07539675Updated Apr 20, 2026

The Multi-Omics Analysis of Lens Zonule Relaxation in The PACG Pathogenesis

An observational study in Primary Angle-Closure Glaucoma, sponsored by Zhongnan Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Zhongnan Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
150
Ages
50 Years and older
Sex
All
01

Study summary

Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and the control group, there are differentially expressed molecules in PACG patients with zonular laxity, and a potential mechanistic network can be constructed therefrom.

Read the detailed description

This study investigates the pathogenesis of PACG by conducting multi-omics analyses of aqueous humor, blood and anterior lens capsule samples from PACG patients with and without concomitant zonular abnormalities, aiming to elucidate the etiology of zonular abnormalities and uncover novel mechanisms underlying their involvement in the pathogenesis of glaucoma.

02

Conditions studied

  • Primary Angle-Closure Glaucoma
03

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

PACG patients with or without zonular laxity, as well as age-related cataract patients without a history or signs of glaucoma who served as the control group.

Inclusion criteria

  • Clinically diagnosed with primary angle-closure glaucoma (PACG)
  • Aged ≥ 50 years, no gender restriction
  • Case Group A: Undergoing glaucoma surgery with intraoperatively confirmed significant zonular laxity
  • Case Group B: Undergoing glaucoma surgery with intraoperatively confirmed normal zonular morphology
  • Control group: age- and sex-matched with case groups; clinically diagnosed with age-related cataract; normal anterior chamber depth and angle; no history or signs of glaucoma; undergoing cataract surgery

Exclusion criteria

Exclusion Criteria:

  • Secondary glaucoma
  • History of previous intraocular surgery
  • Systemic diseases that can cause abnormal ocular zonules
  • Other severe ocular diseases
  • Long-term use of medications affecting connective tissue metabolism
04

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
150 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Case Group A

    PACG patients with zonular laxity

    Other: No Additional Experimental Intervention

  • Case Group B

    PACG patients without zonular laxity

    Other: No Additional Experimental Intervention

  • Control Group

    cataract patients without a history or signs of glaucoma

    Other: No Additional Experimental Intervention

Interventions

  • OtherNo Additional Experimental Intervention

    No Additional Experimental Intervention

05

What researchers measure

Primary outcomes

  1. Concentration of differentially expressed molecules in PACG patients with zonular laxity

    Compared with primary angle-closure glaucoma (PACG) patients without zonular laxity and healthy control subjects, differentially expressed molecules will be identified and quantified by high-throughput omics sequencing and bioinformatics analysis in PACG patients with zonular laxity, and a potential mechanistic network will be constructed based on these molecular changes.

    Time frame: 2 years

06

Study locations

1 of 1 sites recruiting
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430000, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07539675
Lead sponsor
Zhongnan Hospital
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Oct 1, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Min Ke, doctor
Contact
Keminyk@163.com
18672395959
Xiaomin Chen, doctor
Contact
xminchen@whu.edu.cn
13657237773
Wen Zeng, doctor
study director · Zhongnan Hospital
Nan Zhang, doctor
study director · Zhongnan Hospital
Xuetian Yu, student
principal investigator · The Second Clinical College of Wuhan University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion